During a session at the 2025 LeadingAge Annual Meeting in Boston, industry leaders discussed the importance of data sharing ...
Cullinan Therapeutics (CGEM) announced new clinical data from its Phase 1 study of CLN-049 ... bone marrow blasts less than5%, 33% patients were MRD negative by flow cytometry; relapse was not ...
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback